Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
| ▸ | MMP17 | Q9ULZ9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4861469 | 0.90 | KMT2A (0.34) | SRC | |
| SCHEMBL4862478 | 0.89 | SRC (0.33) | SRC | |
| SCHEMBL4864472 | 0.83 | — | — | |
| SCHEMBL4864188 | 0.78 | SYK (0.36) | SRC | |
| SCHEMBL4862729 | 0.76 | MAPT (0.32) | SRC | |
| SCHEMBL1595043 | 0.76 | RXFP1 (0.33) | SRC | |
| SCHEMBL1595047 | 0.76 | RXFP1 (0.33) | SRC | |
| SCHEMBL1595920 | 0.75 | POLB (0.33) | — | |
| SCHEMBL1595923 | 0.75 | POLB (0.33) | — | |
| SCHEMBL4869256 | 0.75 | SRC (0.31) | SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332485-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-02-19 | — | — | US | claimed |
| US-20060160802-A1 | Peptide deformylase inhibitors | GLAXO GROUP LIMITED | 2006-07-20 | — | — | US | claimed |
| WO-2005005456-A2 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | claimed |
| US-7332485-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060160802-A1 | Peptide deformylase inhibitors | GLAXO GROUP LIMITED | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160802-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | SRC 4533/4885MMP2 857/4885MMP3 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.